Delayed release softgel capsules comprise a fill material and a pH dependent shell composition, characterized in that the delayed release nature of the capsules may be achieved without a pH dependent coating or added conventional pH dependent polymers. The delayed release softgel capsules described herein are particularly suitable for initiating release of the active agent in a target location in the colon environment.

The present invention relates to bioavailable fill compositions containing one or more of a decongestant, an expectorant, an antitussive, an analgesic, and/or an antihistamine; capsules filled with the bioavailable fill compositions; and methods of making same.

The present invention relates to an amorphous solid dispersion comprising ABX464 and at least one pharmaceutically acceptable carrier. The present invention also concerns a pharmaceutical composition comprising said ASD, processes for their preparation, an ASD obtainable by specific processes, their use as a medicament and more particularly their use in the treatment and/or prevention of inflammatory diseases, diseases caused by viruses and/or cancer or dysplasia.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

One aim of the present invention is to treat or prevent chronic kidney disease. Provided is a treatment or prophylactic pharmaceutical composition for chronic kidney disease, that contains an SGLTl-inhibiting compound or a pharmaceutically acceptable salt thereof.

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

A compartmented hard shell capsule for containing active formulations, and methods and apparatuses for forming, filling and encapsulating the compartmented hard shell capsules. The compartmented hard shell capsule includes a cap portion and a body portion. The cap portion has a hollow cavity defining a cap chamber. The body portion can be removably inserted into the cap portion. The body portion has an open end, a closed end and a sidewall defining a hollow cavity and a serrated edge along the open end. The serrated edge may be folded over to form a barrier to enclose the body portion, thereby creating a body chamber that is separate from the cap chamber when the body portion is inserted into the cap portion. The methods for filling and encapsulating the compartmented hard shell capsules can be completed in one continuous process, which increases cost-effectiveness for use of the compartmented hard shell capsules.

Provided herein are dendrimers comprising a core unit, five generations of building units being a lysine residue or analogue thereof, a plurality of first terminal groups each comprising a residue of a nucleoside analogue, and a plurality of second terminal groups each comprising a hydrophilic polymeric group. Also provided herein are pharmaceutical compositions comprising the dendrimer, and methods and uses of the dendrimers in therapy of disorders such as cancers.

The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.